Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (81-90 of 391) with videos related to

Pageof 40
Sort By:
Respirology (Carlton, Vic.)|April 1, 2015
Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung diseaseToby M Maher, Amanda Piper, Yuanlin Song, et al.
American Journal of Respiratory and Critical Care Medicine|June 4, 2013
Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a timePaolo Spagnolo, Fabrizio Luppi, Toby M Maher, et al.
Journal of Medical Case Reports|January 12, 2010
Pulmonary fibrosis associated with psychotropic drug therapy: a case reportClare Thornton, Toby M Maher, David Hansell, et al.
Respirology (Carlton, Vic.)|May 9, 2012
Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosisRajeev K Amar, Susan S Jick, Daniel Rosenberg, et al.
ERJ Open Research|October 27, 2022
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosisToby M Maher, Christina Schlecker, Doreen Luedtke, et al.
Respiration; International Review of Thoracic Diseases|June 9, 2012
Incidence of the pneumoconioses in the United Kingdom general population between 1997 and 2008Rajeev K Amar, Susan S Jick, Daniel Rosenberg, et al.
Advances in Therapy|December 27, 2021
Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian FrameworkBryony Langford, Alex Diamantopoulos, Toby M Maher, et al.
ERJ Open Research|March 1, 2021
Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic reviewAnna-Maria Hoffmann-Vold, Toby M Maher, Edward E Philpot, et al.
Thorax|February 14, 2013
Exercise-induced haemoptysis: a thoroughbred cause?James H Hull, Andrew Menzies-Gow, Andrew G Nicholson, et al.
ERJ Open Research|September 2, 2021
Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 eraGizal Nakshbandi, Catharina C Moor, Kerri A Johannson, et al.
Pageof 40

Showing results (81-90 of 391) with videos related to

Sort By:
Pageof 40
Respirology (Carlton, Vic.)|April 1, 2015
Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung diseaseToby M Maher, Amanda Piper, Yuanlin Song, et al.
American Journal of Respiratory and Critical Care Medicine|June 4, 2013
Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a timePaolo Spagnolo, Fabrizio Luppi, Toby M Maher, et al.
Journal of Medical Case Reports|January 12, 2010
Pulmonary fibrosis associated with psychotropic drug therapy: a case reportClare Thornton, Toby M Maher, David Hansell, et al.
Respirology (Carlton, Vic.)|May 9, 2012
Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosisRajeev K Amar, Susan S Jick, Daniel Rosenberg, et al.
ERJ Open Research|October 27, 2022
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosisToby M Maher, Christina Schlecker, Doreen Luedtke, et al.
Respiration; International Review of Thoracic Diseases|June 9, 2012
Incidence of the pneumoconioses in the United Kingdom general population between 1997 and 2008Rajeev K Amar, Susan S Jick, Daniel Rosenberg, et al.
Advances in Therapy|December 27, 2021
Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian FrameworkBryony Langford, Alex Diamantopoulos, Toby M Maher, et al.
ERJ Open Research|March 1, 2021
Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic reviewAnna-Maria Hoffmann-Vold, Toby M Maher, Edward E Philpot, et al.
Thorax|February 14, 2013
Exercise-induced haemoptysis: a thoroughbred cause?James H Hull, Andrew Menzies-Gow, Andrew G Nicholson, et al.
ERJ Open Research|September 2, 2021
Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 eraGizal Nakshbandi, Catharina C Moor, Kerri A Johannson, et al.
Pageof 40